Background: Skin delivery of a therapeutically effective drug is imperative for local cutaneous leishmaniasis (CL) treatment.
Objective: This study aimed to formulate, optimize, and characterize curcumin-loaded nanoemulgel for enhanced skin drug retention to treat CL locally.
Methods: Nanoemulsions were prepared by high-speed homogenization, characterized, and optimized for size, PDI, zeta potential, stability, morphology, drug contents, encapsulation efficiency, drug release, antileishmanial activity, and cell viability. The optimized nanoemulsion (C3) was then incorporated into a carbopol-based gel and evaluated for pH, viscosity, spreadability, and drug release. Both formulations were then assessed for and skin permeation/retention, and pharmacokinetic analysis.
Results: All nanoemulsion formulations had size in nano range with negative surface charge, homogeneously distributed, with spherical droplet geometries, where C3 being highly stable, had good encapsulation efficiency and drug contents (85 ± 5.4 and 68 ± 3.2%), released 90% of drug within 4 h, while C3 gel released the drug significantly sustained up to 46% in 24 h. The C3 formulation demonstrated significant antileishmanial activity across all tested concentrations, while the IC value against NIH3T3 fibroblasts was 0.6202 mM (Log IC: 2.7, : 0.98). The C3 gel showed significantly low skin permeation (341.7 ± 43.6 and 52.6 ± 8.9 µg) with significantly higher skin drug retention (129.5 ± 16.7 and 190.2 ± 33.4 µg) and , with significantly lower , AUC, and AUC.
Conclusion: These results suggested that curcumin nanoemulgel could be an effective alternative strategy for treating CL locally.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/03639045.2025.2473495 | DOI Listing |
Endocr Regul
January 2025
1Endocrinology and Internal Medicine Department, Fattouma Bourguiba University Hospital, Monastir, Tunisia.
Pituitary neuroendocrine tumors (PitNETS) are common intracranial tumors, but extrasellar or ectopic PitNETS are very rare and supposed to originate from some pituitary remnants. They are mostly found in sphenoidal sinus. But particularly, ectopic clival PitNETS are highly aggressive and can cause bone invasion and can be misdiagnosed as other lesions of the skull base such as chordomas.
View Article and Find Full Text PDFACS Sens
March 2025
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221002, Jiangsu, China.
Traditional biological detection methods rely on signal amplification strategies such as enzymatic catalysis or nucleic acid amplification. However, their efficiency decreases in low-temperature environments, compromising their detection sensitivity. To break the loss of enzyme catalytic activity at low temperatures, research on cold-adaptive nanozymes has attracted much attention.
View Article and Find Full Text PDFMol Pharm
March 2025
Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Positive surgical margins following radical prostatectomy significantly contribute to tumor recurrence. While systemic chemotherapy demonstrates limited efficacy in this context, local chemotherapy drug delivery systems based on nanomaterials offer promising strategies to address this issue by modifying drug release kinetics and distribution, thereby enhancing antitumor effects while minimizing the toxicities associated with systemic chemotherapy. In this study, we utilized electrospun nanofibrous mats loaded with docetaxel for sustained drug delivery.
View Article and Find Full Text PDFPediatr Infect Dis J
March 2025
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.
Background: Congenital cytomegalovirus is the leading cause of nongenetic sensorineural hearing loss. Treatment with (val)ganciclovir improves audiologic outcomes. Neutropenia is a common adverse event, but correlates that predict who will develop neutropenia have not been identified.
View Article and Find Full Text PDFThe development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of chromosome 1q (1q+) is the most frequent arm-level copy number gain in patients with MM and is associated with higher risk of progression and death despite recent therapeutic advances. Thus, developing targeted therapy for MM patients with 1q+ stands to benefit a large portion of patients in need of more effective management.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!